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Introduction
The worldwide spread of pathogenic bacteria that
are resistant to a variety of antibiotics threatens to
reduce modern medicine to a state reminiscent of
the preantibiotic era. Although novel antibiotics are
developed against such resistant bacteria, by spend-
ing extensive funds, the pathogens ultimately be-
come resistant to such drugs. To break this vicious
cycle, it will be necessary to adopt chemotherapy-
independent remedial strategies to combat bacterial
infections. Bacteriophages (phages) are the viruses
that specifically infect and lyse the bacteria. Phage
therapy, a method using phages for the treatment
of bacterial infections, was introduced by Felix
d’Herelle, who codiscovered phages in about 1920
(Summers, 1999). This discovery occurred about
20 years before practical application of penicillin,
the first antibiotic. At the time of its discovery,
phage therapy was regarded as a possible treatment
method against bacterial infectious diseases (Ho,
2001; Sulakvelidze 2001). Although phage therapy
was used to treat and prevent bacterial infectious
diseases in the former Soviet Union and Eastern
Europe (Slopek, 1987; Alisky, 1998; Weber-
Dabrowska, 2000; Chanishvili, 2002), it was aban-
doned by the West in the 1940s with the arrival of
the antibiotic era. However, the ongoing evolution
of bacterial multidrug resistance has recently mo-
tivated the Western scientific community to reeval-
uate phage therapy for bacterial infections that are
incurable by conventional chemotherapy (Barrow,
1997; Pirisi, 2000; Merrill, 2003).
History
Ernst Hankin in 1896 for the first time reported the
presence of marked antibacterial activity (against
Vibrio cholera) in the waters of Ganga and Jamuna
Rivers in India. However, the bacteriophages were
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Abstract
The injudicious use of antibiotics not only in medicine but also to promote the growth of farm animals has led to the devel-
opment of antibiotic resistance against many bacterial diseases. One of the remedy against such drug resistant bacterial in-
fections is the application of phage (Bacteriophage) therapy. Phage therapy involves using phages or their products as
bioagents for the treatment or prophylaxis of bacterial infections. There are two types of phages based on their type of life
cycle: the lytic and the lysogenic phages. Only the lytic phages are used in phage therapy, because of the disadvantages of
lysogenic pahges (Superinfection immunity, lysogenic conversion, specialized transduction). Apart from live phages the
phage byproducts like phage lysins can also be used specifically against certain bacterial infections. The reports indicate that
appropriate administration of living phages can be used to treat lethal infectious diseases caused by bacteria, like Pseudomonas
aeruginosa, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Salmonella spp. and Staphylococcus aureus
etc. In the coming time the phage therapy will compensate for unavoidable complications of antimicrobial therapy, particularly
the appearance of multidrug resistance bacteria (super bugs).
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discovered by Frederick Twort and Felix d'Hérelle
in 1915 and 1917, respectively (Shasha et al.,
2004). The phage therapy was immediately recog-
nized by many to be a key way forward for the
eradication of bacterial infections. George Eliava,
from Georgia  travelled to the Pasteur Institute in
Paris where he met d'Hérelle, and in 1923 he
founded the Eliava Institute in Tbilisi, Georgia, de-
voted to the development of phage therapy. Whilst
knowledge was being accumulated regarding the
biology of phages and how to use phage cocktails
correctly, early uses of phage therapy were often
unreliable. When antibiotics were discovered in
1941 and marketed widely in the USA and Europe,
Western scientists mostly lost interest in further use
and study of phage therapy for some time (Hanlon,
2007). The Russian scientists continued to develop
already successful phage therapy to treat the
wounds of soldiers in field hospitals. During World
War II, the Soviet Union used bacteriophages to
treat many soldiers infected with various bacterial
diseases e.g. dysentery and gangrene. Russian re-
searchers continued to develop and to refine their
treatments and to publish their research and results
(Summers, 2001). There is an extensive library and
research center at the Eliava Institute in Tbilisi,
Georgia. Phage therapy is today a widespread form
of treatment in that region. For 80 years Georgian
doctors have been treating local people, including
babies and newborns, with phages. As a result of
the development of antibiotic resistance since the
1950s and an advancement of scientific knowledge,
there has been renewed interest worldwide in the
ability of phage therapy to eradicate bacterial in-
fections and chronic polymicrobial biofilm, along
with other strategies.
Life cycle and mechanism of bacteriolysis of
phages
Besides, morphological classification, phages can
be divided into roughly two groups according to
their life cycle. The “lytic phage,” which repeats a
cycle in which self-proliferation is synchronous
with destruction of bacteria (lytic cycle). The lytic
cycle is completed in five steps: The adsorption of
the phage to the complementary receptor site on the
bacterial cell is first step, it then penetrates into the
bacterial host, followed by intracellular develop-
ment, maturation and finally release of virions from
the host cell e.g., KVP20, KVP40, KVP241 and T-
even phages. The second type of life cycle the
“lysogenic cycle,” has a lysogenic cycle in addition
to a lytic cycle. In the lysogenic cycle, the phage
genome is integrated into the bacterial genome and
the phage genome multiplies cooperatively with
the host bacteria without destroying it. However,
by UV light or certain chemicals or a rare sponta-
neous event can lead to popping out of phage DNA
and initiation of the lytic cycle e.g. fMR11. Bacte-
rial strains that integrate the phage genome into
their genome are known as lysogens and they are
resistant to infection by phages that are genetically
related to previously lysogenized phages. Some
lysogenic phages have toxic genes in their genome
(Bradbury, 2004; Kaneko, 1997; Yamaguchi,
2000). For these reasons, the lytic phages are




Superinfection immunity means lysogenic cells are
immune to reinfection by the same phage. Phage
genes c1+,c11+,c111+ are responsible for it, espe-
cially c1 which codes for immunity repressor
which binds with operator genes OL and OR
which govern expression of Cro+ gene that is re-
quired for activation of lytic cycle. UV light causes
increased levels of RecA protein that cleaves c1+
hence causes reversion to lytic cycle.
II. Lysogenic conversion:
Lysogenic conversion means the host cell may ex-
hibit new properties. For example, Prophage of
Corynebacterium diptheriae, Clostridium botu-
linum, Vibrio cholera, Streptococcus spp. carries
genes for their toxin production and hence makes
them pathogenic. Similarly colonies of Bacillus
megatherium change from smooth to rough by
prophage.
III. Specialised transduction: 
Specialized transduction means upon excision,
viral genome carries with it the adjacent genes from
bacterial genome and can transduce them into the
bacterial cell that is lacking those genes. It occurs
due to unusual excision events. For example, phage
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Lambda is a specialized transducing phage for gal
and bio genes; phage80 for tryptophan genes and
phage P22 is a transducing phage for proline genes
in E. coli.
Therapy using living phages
Two types of phage therapy have been distin-
guished: passive (where the initial phage dose re-
moves the pathogen) and active (where the effect
is due to the in vivo replication of the phage on the
pathogen). Georgian Scientists have been using it
for more than 80 years. In the 1980s, Smith and
coworkers undertook rigorous investigations into
phage therapy for pathogenic E. coli infections in
a veterinary context (Smith and Huggins, 1982,
1983,1987), thereby reopening this field of re-
search in Western countries. Smith and coworkers
showed that a single intramuscular dose of one
anti-K1 phage is more effective for treating mice
challenged with E. coli intramuscularly or intrac-
erebrally than multiple intramuscular doses of
tetracycline, ampicillin, chloramphenicol, or
trimethoprim plus sulfafurazole. Staphylococcus
aureus is a pathogen of pyogenic inflammatory dis-
eases, food poisoning, toxic shock syndrome and
is also a major causative agent for opportunistic
and/or nosocomial infections and often results in
high mortality rates (Noble, 1998). More than 50%
of clinical S. aureus isolates in Japan today carry
multidrug resistance and are generally referred to
as methicillin-resistant S. aureus (MRSA) (Hira-
matsu, 2001; Shimada, 2002). Moreover, certain
MRSA strains have already acquired low sensitiv-
ity or resistance to vancomycin, a unique antibiotic
previously considered effective against MRSA,
e.g., vancomycin intermediate S. aureus (VISA)
(Hiramatsu, 1997) or vancomycin-resistant S. au-
reus (VRSA) (Chang et al., 2003; Kacica, 2004).
Furthermore, S. aureus strains resistant to linezolid,
a recently developed novel synthetic antibiotic, are
already reported to be present in the United States
and Europe (Pillai, 2002). Therefore, possibility of
phage therapy was developed for S. aureus infec-
tious disease. Recently, a staphylococcal phage (2
x 109) was shown to prevent abscess formation in
a rabbit model of wound infection in which it was
injected simultaneously with 8 x 107 S. aureus cells
into a subcutaneous site. This result indicates that
phages may be a valuable prophylaxis against
staphylococcal infection (Wills, 2005). Further-
more, in hand-wash studies in situ, a phage-en-
riched wash solution resulted in a 100-fold reduc-
tion in staphylococcal numbers on human skin
compared with a phage-free wash solution (O’Fla-
herty, 2005). These results provide strong evidence
for the usefulness of living staphylococcal phages
as agents for therapy, prophylaxis, and disinfection
of S. aureus infection. There have been many pub-
lished reports examining phage efficacy against ex-
perimental infections by E. coli (Merrill, 1996;
Chibani-Chennoufi, 2004), Pseudomonas aerugi-
nosa (Soothill, 1992; Ahmad, 2002), Acinetobacter
baumanii (Soothill, 1992), Klebsiella pneumonia
(Bogovazova et al., 1991, 1992), Enterococcus fae-
cium (vancomycin- resistant strain) (Biswas,
2002), Vibrio vulnificus (Cerveny, 2002) and Sal-
monella spp. (Toro, 2005) in animal models.
The effectiveness of phage administration for
the control of fish diseases and for food disinfec-
tion has also been documented. Nakai et al. (1999)
saved the lives of cultured fish challenged by Lac-
tococcus garvieae and Pseudomonas plecoglossi-
cida, which are fish pathogens (Park et al., 2000;
Nakai and Park, 2002). Phages were also shown to
be effective for the elimination of food poisoning
pathogens such as Listeria monocytogenes (Lever-
entz et al., 2003, 2004), Campylobacter jejuni (At-
terbury et al., 2003, Goode et al., 2003) and
Salmonella spp. (Leverentz et al., 2001) from the
surface of foods.
Phages are currently being used to treat post-
burn bacterial infections, which are a major prob-
lem for those recovering from the trauma of
third-degree burns. Within 24 hours, burn patients
can start suffering from opportunistic bacterial at-
tacks. As an alternative to treating post-burn bac-
terial infections by antibiotics, bacteriophages have
been in use in certain parts of the world, such as at
Tbilisi in Georgia and in Poland, and this approach
has now been more widely recognized. Soothill
(1994) demonstrated that use of phages could im-
prove success of skin grafts by reducing the under-
lying P. aerugenosa infections. It has been shown
that bacteriophage therapy has an 80% success rate
against Enterococcus infections and up to 90%
against S. aureus, P. aeruginosa, E. coli and Kleb-
siella pneumoniae (Soothill, 1994). P. aeruginosa
is the most common post-burn infection, and it is
known to be notoriously resistant to a variety of an-
tibiotics. For the most effective treatment of post-
burn infections, a cocktail of bacteriophages is
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sprayed at the site of burns; this will reduce the
chance of the bacteria developing resistance against
the different bacteriophages. Bacteriophage solu-
tions or aerosols can also be used to treat the sur-
faces and instruments in operating rooms as well
as the skin of the surgical patient (prior to surgery).
The bacteriophages can also be used to treat the
chronic infections, refractory to the treatment of an-
tibiotic therapy. Antibiotics fail to cure many
chronic infections caused due to biofilm formation.
Biofilms are complex mixtures of microbes that
typically resist the effects of antibiotics formed in
chronic infections like: chronic and acute urinary
tract infections and cystitis, ear infections (otitis
media), chronic sinusitis (rhino sinusitis), skin in-
fections, intestinal infections, prostatitis and asso-
ciated sexual problems. It is also effective in
infections where blood circulation is poor e.g. os-
teomyelitis, diabetic foot, tropic ulcers, bed sores.
Animal studies
Mice:
In 1980s a careful series of phage therapy experi-
ments in various animals was conducted, which re-
sumed the tradition of the mouse experiments from
the early 1940s. The trial was started with a K1 E.
coli meningitis mouse model. Low doses of phage,
given intramuscularly, protected mice against a
massive dose of pathogen applied in the opposite
muscle at the same time (Smith and Huggins,
1982). The anti-K1 phage was in vivo more effi-
cient than a large number of antibiotics. Multipli-
cation of the phage occurred in the animal, and
phage was disseminated from the site of inocula-
tion into the blood and the spleen, where it was se-
questered. However, phage treatment could not be
delayed for more than 5 h after the pathogen chal-
lenge without loss of activity. Intramuscular phage
also protected against intracerebral pathogen chal-
lenge. Only phages recognizing the K1 antigen
were protective. Phages with high in vitro lytic ac-
tivity were also the most effective in conferring
protection in vivo. The results of Smith and Hug-
gins were reproduced recently (Bull et al., 2002).
Human volunteers showed a very similar faecal
phage excretion pattern to mice (Bruttin and Brüs-
sow, 2005). More than 10% of the orally applied
phage was recovered from the faeces. When the
volunteers were put back on phage-free drinking
water, faecal phage titres quickly dropped below
the threshold of detection when no infective E. coli
strain was present in the gut.
Chickens: 
E. coli causes severe respiratory infections in
broiler chickens. In one study, phages were applied
by aerosol spraying, followed by injection of 104
cfu E. coli directly into the thoracic air sac (Huff
et al., 2002). Aerosol containing 107 phage forming
units (pfu) of two phages halved the mortality
when the challenge was done on the day of phage
spraying. When the dose of the phage was in-
creased to 108 pfu significant protection against in-
fection was still observed up to 3 days after phage
spraying. Another study documented efficacy of
phage applied intramuscularly against lethal E. coli
infections for chickens. When phage and bacteria
were given in equal numbers, no morbidity was ob-
served at all in chicken, but 100-fold lower phage
titers also conferred significant protection, demon-
strating the in-vivo multiplication of the phage. In-
tramuscularly administered phage also protected
against intracranial E. coli infection. Phage therapy
was even effective when given at the onset of clin-
ical symptoms (Barrow et al., 1998). 
Calves: 
Subsequently, Smith and colleagues infected calves
with a natural bovine enteropathogenic E. coli
strain causing high lethality. Convincing evidence
for the efficacy of phage therapy was obtained in
an extremely carefully documented series of exper-
iments (Smith and Huggins, 1982, 1983; Smith et
al., 1987). Diarrhoea could be prevented by phage
given 1–8 h after infection. When phage applica-
tion was delayed until the onset of symptoms,
phage had no effect on diarrhoea, but still largely
prevented death (Smith and Huggins, 1983). Phage
titers increased in the faeces over time, with a con-
comitant decrease in the enteropathogen counts. In
sacrificed animals this observation was confirmed
at all anatomical levels of the gastrointestinal tract.
Phage counts were 10-fold lower in mucosal scrap-
ings than in the luminal content. Phage was not re-
covered from blood or spleen. Phage-resistant cells
were observed in most of the calves, but their titres
generally remained low. Upon reinoculation into
new calves, the mutant cells were less competitive
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than the parental strain. 
Calves held in a room previously occupied by
phage-exposed calves could no longer be infected
with the enteropathogen, coming close to
d’Herelle’s initial idea of ‘infectious protection’ by
phages. Also, spraying the litter of the calves in the
room with a high or low dose of phage (106 pfu.)
prevented an infection of the calves with the path-
ogenic E. coli strain, applied either before or after
transfer to the phage-inoculated room. When sub-
stantial pathogen counts were measured in the fae-
ces, phage appeared with titres 10- to 100-fold
higher than the bacterial counts. Phage survived in
the room for up to a year and at least 100 days
longer than the pathogenic bacteria, and was also
more resistant to phenolic disinfectants than the en-
teropathogen (Smith et al., 1987b).
Utilization of phage byproducts to treat bacter-
ial infections
I. Phage Lysin:
Most tailed phages produce peptidoglycan hydro-
lase (endolysin or lysin) to release their progeny at
the final stage of multiplication. Amidase (N-
acetyl-muramyl-l-alanine bond), endopeptidase
(crosslinking peptide bond), or muramidase or lu-
cosaminidase (sugar chain) may be released, de-
pending on the cutting site (Jado et al., 2003).
Lysin is able to degrade peptidoglycan even if it is
made to react from outside the cell wall (Nelson et
al., 2001; Loeffler et al., 2001; Cheng et al., 2005).
Although penicillin and cephalosporin antibiotics
inhibit peptidoglycan synthesis, lysing the bacterial
cell upon cell division, phage lysin destroys the
Peptidoglycan directly, exerting a bacteriolytic ef-
fect within several seconds of administration. It can
also destroy the cell walls of nongrowing bac-
terium which are insensitive to many antibiotics.
The simultaneous administration of two lysins that
have different peptidoglycan cutting sites has a
synergistic effect (Loeffler et al., 2003; Schuch et
al., 2002). Interestingly, except for the lysin of an
enterococcal phage (Yoong et al., 2004), lysin is
fairly specific for bacterial species as well as
phages themselves, indicating that phage lysin can
very likely eliminate the targeted bacteria without
disturbing the normal flora.
In vivo efficacy of lysin treatment has been ex-
amined using mice challenged by Streptococcus
pyogenes (Loeffler et al., 2003), S. pneumoniae,
Bacillus anthracis, (Yoong et al., 2004) and group
B streptococcus (Yoong et al., 2004). Lysin treat-
ment was shown to be effective not only against lo-
calized infections in the nasal cavity or vagina, but
also against systemic infections. Similar results
were obtained using a staphylococcal phage lysin.
II. Protein antibiotics: 
Some small phages such as fX174 or Qb, which
have single stranded DNA or RNA, respectively,
do not have the genes for holin or lysin proteins,
which are expressed by tailed phages to degrade
peptidoglycan as described earlier in this article.
Instead, they produce a protein that inhibits a step
in murein monomer synthesis. The fX174 gene
product, gpE, inhibits MraY, which catalyzes the
formation of the first lipid-linked murein precursor,
and Qb gpA2 inhibits MurA, which catalyzes the
first step in the murein biosynthesis pathway. Inhi-
bition of synthesis of the cell wall is thought to be
a general strategy in small phages that do not pro-
duce holin or lysin; their inhibitory gene products
are known as “protein antibiotics.” If a method can
be developed to transport them efficiently into the
host cytoplasm through the cell membrane, they
would be useful as antibacterial agents.
Advantages of phage therapy over antibiotics
Phage therapy can be very effective in certain con-
ditions and has some unique advantages over an-
tibiotics. Bacteria also develop resistance to
phages, but it is incomparably easier to develop
new phage than new antibiotic. A few weeks versus
years are needed to obtain new phage for new strain
of resistant bacteria. As bacteria evolve resistance,
the relevant phages naturally evolve alongside.
When super bacterium appears, the super phage al-
ready attacks it. We just need to derive it from the
same environment. Phages have special advantage
for localized use, because they penetrate deeper as
long as the infection is present, rather than decrease
rapidly in concentration below the surface like an-
tibiotics. The phages stop reproducing once a spe-
cific bacteria they target are destroyed. Phages do
not develop secondary resistance, which is quite
often in antibiotics. With the increasing incidence
of antibiotic resistant bacteria and a deficit in the
development of new classes of antibiotics to coun-
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teract them, there is a need to apply phages in a
range of infections. 
Application of Bacteriophages
Collection: In its simplest form, phage treatment
works by collecting local samples of water likely
to contain high quantities of bacteria and bacterio-
phages, for example effluent outlets, sewage and
other sources. The samples are taken and applied
to the bacteria that are to be destroyed which have
been cultured on growth medium. The bacteria usu-
ally die, and the mixture is centrifuged. The phages
collect on the top of the mixture and can be drawn
off. The phage solutions are then tested to see
which ones show growth suppression effects
(lysogeny) and/or destruction (lysis) of the target
bacteria. The phage showing lysis are then ampli-
fied on cultures of the target bacteria, passed
through a filter to remove all but the phages, then
distributed.
Treatment: 
Phages are "bacterium specific" and it is therefore
necessary in many cases to take a swab from the
patient and culture it prior to treatment. Occasion-
ally, isolation of therapeutic phages can typically
require a few months to complete, but clinics gen-
erally keep supplies of phage cocktails for the most
common bacterial strains in a geographical area.
Phages in practice are applied orally, topically on
infected wounds or spread onto surfaces, or used
during surgical procedures. Injection is rarely used,
avoiding any risks of trace chemical contaminants
that may be present from the bacteria amplification
stage and recognizing that the immune system nat-
urally fights against viruses introduced into the
bloodstream or lymphatic system.
Distribution: 
Phages can usually be freeze dried and turned into
pills without materially impacting efficacy. In pill
form temperature stability up to 55oC, and shelf
lives of 14 months have been shown. Other forms
of administration can include application in liquid
form. These vials are usually best kept refrigerated.
Oral administration works better when an antacid
is included, as this increases the number of phages
surviving passage through the stomach. Topical ad-
ministration often involves application to gauzes. 
Problems to overcome
In phage therapy, the following problems remain
to be solved: (i) inactivation of administered
phages or lysin by a neutralizing antibody and al-
lergic reactions to them, (ii) liberation of endotox-
ins as a consequence of widespread lysis of bacteria
within the body. (iii) The negative public percep-
tion of viruses. 
Regarding the first problem, decreases in the
therapeutic effect with multiple administrations
have not been shown, nor have side effects such as
allergies been observed for phages or lysin, al-
though antibodies against them have been detected
in mouse blood (Stone, 2002). To circumvent this
problem, nevertheless, phages or lysins with differ-
ent antigenicities or with low immunogenicities
could be prepared. Liberation of endotoxins is a
minor effect and also such effects may be observed
when antibiotics are used. The third problem can
be overcome by increasing the awareness among
people about the benefits of phage therapy.
Conclusion 
Phages will not be the panacea of medicine, but
phage therapy research will gain momentum be-
cause traditional antibiotic research has come to a
stop. Appropriately selected phages can easily be
used to help prevent bacterial diseases in humans
or animals, with potential for alternative applica-
tions and special interest for developing countries.
Much of the evidence strongly shows that appro-
priately administered phage therapy is very effec-
tive for treatment and prevention of many kinds of
bacterial infectious diseases, especially those
caused by multidrug-resistant bacteria. Currently,
many pathogenic bacteria have acquired multiple
drug resistance, which is a serious clinical problem.
Although some problems remain to be solved,
many experts are of the opinion that phage therapy
will find a niche in modern Western medicine in
the future.
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